Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lumason Contrast-Enhanced Ultrasound Clear all
Completed Early Phase 1 Interventional

Comparison of Three Methods for Early Detection of Breast Cancer

NCT03954015
View directory record Official record
Conditions
Proliferative Breast Disease
Interventions
Contrast Enhanced imaging, Lumason
Diagnostic Test · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 23, 2026, 10:06 AM EDT
Terminated Early Phase 1 Interventional

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

NCT04150874
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Lumason®
Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Results available

BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury

NCT05025449
View directory record Official record
Conditions
Abdominal Trauma
Interventions
Focused Assessment with Sonography for Trauma (FAST), Bubble-Enhanced FAST (BEFAST)
Diagnostic Test · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 1Phase 2 Interventional

Contrast Ultrasound for Pediatric Trauma - Comparative Evaluation (CAPTURE Study)

NCT04718441
View directory record Official record
Conditions
Abdominal Injury
Interventions
Lumason
Drug
Lead sponsor
David Mooney
Other
Eligibility
8 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Phoenix, Arizona • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 23, 2026, 10:06 AM EDT
Not yet recruiting Phase 1 Interventional

Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

NCT03653702
View directory record Official record
Conditions
Vesico-Ureteral Reflux
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 35 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas

NCT03357081
View directory record Official record
Conditions
Hematoma
Interventions
CEUS or Contrast enhanced Ultrasound
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD

NCT05186415
View directory record Official record
Conditions
Tetralogy of Fallot, Pulmonary Insufficiency
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Completed No phase listed Observational

Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason

NCT03492944
View directory record Official record
Conditions
Crohn Disease
Interventions
Ultrasound Microbubble Contrast Agent, Ultrasound Imaging
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Terminated Phase 4 Interventional Results available

Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

NCT03040323
View directory record Official record
Conditions
Liver Biopsy
Interventions
Lumason 60.7Mg Powder for Injection, Placebos
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 23, 2026, 10:06 AM EDT
Withdrawn Not applicable Interventional

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

NCT03300401
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
Drug · Device · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 23, 2026, 10:06 AM EDT
Terminated Phase 1 Interventional

Contrast-Enhanced Ultrasound for Kidney Transplant

NCT02911714
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Lumason Contrast-Enhanced Ultrasound
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 23, 2026, 10:06 AM EDT
Withdrawn Phase 4 Interventional

Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients

NCT03963999
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Bone Marrow Transplant Complications, Stem Cell Transplant Complications
Interventions
Ultrasound Elastography, Contrast Enhanced Ultrasound (CEUS)
Diagnostic Test · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Month to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 23, 2026, 10:06 AM EDT
Recruiting Phase 2 Interventional

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

NCT05641935
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma
Interventions
Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
john eisenbrey
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Recruiting Early Phase 1 Interventional

Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH

NCT03107520
View directory record Official record
Conditions
Developmental Dysplasia of the Hip
Interventions
Intraoperative contrast-enhanced ultrasound (CEUS), Lumason
Diagnostic Test · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 24 Months
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Recruiting Phase 2 Interventional

CEUS Evaluation of Hydrocephalus in Neonates and Infants

NCT06693752
View directory record Official record
Conditions
Hydrocephalus in Infants, Hydrocephalus Acquired
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238
View directory record Official record
Conditions
Kidney Cancer
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Contrast Enhanced Ultrasound in COVID-19

NCT04640038
View directory record Official record
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease

NCT03335020
View directory record Official record
Conditions
Fibromuscular Dysplasia of Arteries, Segmental Arterial Mediolysis, Spontaneous Coronary Artery Dissection, Atherosclerosis of Artery
Interventions
Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging, 3-D Volume Ultrasound
Device · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 23, 2026, 10:06 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Contrast-Enhanced Ultrasound

NCT03473249
View directory record Official record
Conditions
Abdominal Injuries, Physical Abuse, Accidental Fall, Motor Vehicle Injury
Interventions
Contrast-Enhanced Ultrasound using Lumason
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 23, 2026, 10:06 AM EDT
Recruiting Phase 4 Interventional

CEUS for Blunt Abdominal Trauma in Children

NCT03490929
View directory record Official record
Conditions
Trauma Abdomen
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 10:06 AM EDT
Terminated Phase 4 Interventional Results available

Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

NCT03821376
View directory record Official record
Conditions
Renal Malignant Tumor
Interventions
Contrast enhanced ultrasound with Lumason
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

CEUS Evaluation of Hypoxic Ischemic Injury

NCT03549520
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 18 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 23, 2026, 10:06 AM EDT